Large library docking for novel SARS‐CoV ‐2 main protease non‐covalent and covalent inhibitors
Protein Science · 2023
DOI: 10.1002/pro.4712 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein Science, 2023. Verfasst von Elissa A Fink und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, University of California-San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIGMS NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Antiviral therapeutics to treat SARS‐CoV‐2 are needed to diminish the morbidity of the ongoing COVID‐19 pandemic. A well‐precedented drug target is the main viral protease (M Pro ), which is targeted by an approved drug and by several investigational drugs. Emerging viral resistance has made new inhibitor chemotypes more pressing. Adopting a structure‐based approach, we docked 1.2 billion non‐covalent lead‐like molecules and a new library of 6.5 million electrophiles against the enzyme structure. From these, 29 non‐covalent and 11 covalent inhibitors were identified in 37 series, the most potent having an IC 50 of 29 and 20 μM, respectively. Several series were optimized, resulting in low micromolar inhibitors. Subsequent crystallography confirmed the docking predicted binding modes and may template further optimization. While the new chemotypes may aid further optimization of M Pro inhibitors for SARS‐CoV‐2, the modest success rate also reveals weaknesses in our approach for challenging targets like M Pro versus other targets where it has been more successful, and versus other structure‐based techniques against M Pro itself.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, University of California-San Francisco, San Francisco, California, USA.
- Graduate Program in Biophysics, University of California-San Francisco, San Francisco, California, USA.
- Graduate Program in Chemistry and Chemical Biology, University of California-San Francisco, San Francisco, California, USA.
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California-San Diego, San Diego, California, USA.
ORCID-Profile: Brian K Shoichet
Förderung
- NIH HHS
- NIGMS NIH HHS
- NIAID NIH HHS
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- U.S. Department of Defense
- Defense Advanced Research Projects Agency
Zitieren
APA
Fink, E. A., Bardine, C., Gahbauer, S., Singh, I., Detomasi, T. C., White, K., Gu, S., Wan, X., Chen, J., Ary, B., Glenn, I., O'Connell, J., O'Donnell, H., Fajtová, P., Lyu, J., Vigneron, S., Young, N. J., Kondratov, I. S., Alisoltani, A., …, & Craik, C. S. (2023). Large library docking for novel SARS‐CoV ‐2 main protease non‐covalent and covalent inhibitors. Protein Science. https://doi.org/10.1002/pro.4712
Vancouver
Fink EA, Bardine C, Gahbauer S, Singh I, Detomasi TC, White K, et al. Large library docking for novel SARS‐CoV ‐2 main protease non‐covalent and covalent inhibitors. Protein Science. 2023. doi:10.1002/pro.4712
BibTeX
@article{Fink2023,
author = {Fink, Elissa A and Bardine, Conner and Gahbauer, Stefan and Singh, Isha and Detomasi, Tyler C and White, Kris and Gu, Shuo and Wan, Xiaobo and Chen, Jun and Ary, Beatrice and Glenn, Isabella and O'Connell, Joseph and O'Donnell, Henry and Fajtová, Pavla and Lyu, Jiankun and Vigneron, Seth and Young, Nicholas J and Kondratov, Ivan S and Alisoltani, Arghavan and Simons, Lacy M and Lorenzo-Redondo, Ramon and Ozer, Egon A and Hultquist, Judd F and O'Donoghue, Anthony J and Moroz, Yurii S and Taunton, Jack and Renslo, Adam R and Irwin, John J and García-Sastre, Adolfo and Shoichet, Brian K and Craik, Charles S},
title = {Large library docking for novel SARS‐CoV ‐2 main protease non‐covalent and covalent inhibitors},
journal = {Protein Science},
year = {2023},
doi = {10.1002/pro.4712}
}
EUVIMED